NEW YORK – OpGen is forging its core technologies into highly multiplexed molecular diagnostic assays to detect pathogens and resistance genes. While companies in the rapid antimicrobial resistance (AMR) space in general have struggled to achieve a good valuation of their technologies and remain financially solvent, OpGen's collaborations have recently made a difference to its bottom line.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.